acute coronary syndrome
Conditions
Interventions
Treatment group:Allopurinol Sustained-reease Capsules
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) the people who understand and would sign the informed consent voluntarily; 2) Aged 18 to 80 years old; 3) hospitalized patients diagnosed as acute coronary syndrome in the past 1 months; a) hsCRP > 2mg/L; b) allopurinol allergy gene HLA-B5801 was negative.
Exclusion criteria
Exclusion criteria: 1) history of coronary artery bypass grafting; 2) allergy to allopurinol or any excipient; 3) administration of allopurinol or other uric-acid-lowering drugs within 7 days before randomization; 4) abnormal liver function (ALT >1.5 fold of the upper limit); 5) renal dysfunction (creatinine clearance rate <45 ml/min); 6) thrombocytopenia (PLT<100g/L); 7) gout patients; 8) uncontrolled infectious diseases in screening period; 9) Thyroid dysfunction, moderate to severe anemia (hemoglobin < 90g/L), systemic lupus erythematosus, malignant hematopathy, leukopenia, asthma, inflammatory bowel disease and other immune diseases were found during the screening period; 10) Non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs not included in the study protocol should be taken for a long time during the study period; 11) the history of surgery or interventional operation within 6 months before the screening period; 12) patients with mental disorders such as anxiety or depression; 13) pregnant women, lactating women or women of childbearing age who did not use effective contraceptive measures 14) patients who participated in other clinical trials 3 months before the screening period; 15) the researchers judged that patients were not suitable for other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of low attenuation plaque volume measured by coronary CTA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of total plaque volume measured by coronary CTA;Changes of restructure index measured by coronary CTA;Changes of inflammatory factors in plasma;Changes of caspase-1 and SOD in plasma;All-cause mortality;Readmission rate of acute coronary syndrome; | — |
Countries
China
Contacts
Public ContactXiang Cheng
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed